Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-26T02:48:04.712Z Has data issue: false hasContentIssue false
  • English
  • Français

Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes?

Published online by Cambridge University Press:  01 September 2022

A. Llimona González ,
M. Calls Samora ,
D. García Hernández  and
S. Oller Canet
A. Llimona González*
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
M. Calls Samora
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
D. García Hernández
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
S. Oller Canet
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Acute Confusional Syndrome (ACS) is the most common neuropsychiatric complication in COVID-19 infection. Its management is still a challenge because the data and recommendations based on the evidence are limited.

Objectives

To describe the differential characteristics in the management of ACS in patients with COVID-19 pneumonia compared to ACS secondary to other causes.

Methods

We present a descriptive study that is has been carried out in 62 patients with ACS (26 of them diagnosed with COVID 19 pneumonia), who have required assessment by the liaison psychiatry service of Hospital del Mar between February and April, 2020. The sample was divided in 2 groups (with and without COVID 19 pneumonia). Chi square and Fisher’s tests were used to comparisons.

Results

Dexmetomidine (26 vs 0) and olanzapine (13 vs 3) were significantly more frequently used in COVID-19 patients (p< 0 001). A greater number of different antipsychotic drugs were used in COVID 19 patients (2.40± 1 323 number of drugs), (p<0.0001). Further neuroimaging tests were requested in COVID 19 patients and they received less family support (4) compared to non COVID-19 (22), (p<0.005).

Conclusions

ACS associated with COVID-19 pneumonia in the patients in our sample is more difficult to manage than ACS associated with other pathologies, similar to which described in other series. It is associated with a longer duration of confusional symptoms and difficulties for control it.

Disclosure

No significant relationships.

Keywords

deliriumACUTE CONFUSIONAL COVID-19CONFUSIONALCovid-19
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S308
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.